חזרה לתוצאות החיפוש

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Amyotrophic Lateral Sclerosis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • St Joseph's Hospital and medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States

    Contact: Study coordinator (Dr S Ladha, Doctor of Medicine) · fulton.research@commonspirit.org · (602) 406-6262
    Contact: Principal Investigator (Dr Shafeeq Ladha, Doctor of Medicine)

  • University of California San Diego Medical Center, San Diego, California, United States

    Contact: Study coordinator (Dr John Ravits, Doctor of Medicine) · jravits@health.ucsd.edu · (858) 246-1154
    Contact: Principal Investigator (Dr John Ravits, Doctor of Medicine)

  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Dr Bjorn Oskarsson, Doctor of Medicine) · oskarsson.bjorn@mayo.edu · (904) 953-0407
    Contact: Principal Investigator (Dr Bjorn Oskarsson, Doctor of Medicine)

  • University of Miami School of Science, Miami, Florida, United States

    Contact: Study coordinator (Dr Michael Benatar, Doctor of Medicine) · mbenatar@med.miami.edu · (305) 243-6480
    Contact: Principal Investigator (Dr Michael Benatar, Doctor of Medicine)

  • Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Winifred Asigri Study Coordinator) · pioneeralshealey@mgb.org · (617) 724-5659
    Contact: Principal Investigator (Dr Doreen Ho, Doctor of Medicine)

  • Herbert Irving Comprehensive Cancer Center, New York, New York, United States

    Contact: Study coordinator (Dr Neil Schneider, Doctor of Medicine) · ns327@columbia.edu · (212) 342-3107
    Contact: Principal Investigator (Dr Neil Schneider, Doctor of Medicine)

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Spriha Thapa Study Coordinator) · Spriha.Thapa@pennmedicine.upenn.edu · 267-610-8822
    Contact: Principal Investigator (Dr Colin Quinn, Doctor of Medicine)

  • UZ Leuven, Leuven, Belgium

    Contact: Study coordinator (Evi Parente Study Coordinator) · evi.parente@uzleuven.be · + 32 1638668
    Contact: Study coordinator (Ann Dhondt Study Coordinator) · ann.dhondt@uzleuven.be · + 32 16347577
    Contact: Principal Investigator (Dr Philip Van Damme, Doctor of Medicine)

  • UMC Utrecht, Utrecht, Netherlands

    Contact: Study coordinator (Prof Leonard Van Den Berg, Doctor of Medicine) · l.h.vandenberg@umcutrecht.nl · +31 887555555
    Contact: Principal Investigator (Prof Leonard Van Den Berg, Doctor of Medicine)

  • Kings College Hospital, London, United Kingdom

    Contact: Study coordinator (Dr Ammar Al-Chalabi, Doctor of Medicine) · ammar.al-chalabi@kcl.ac.uk · +44 2032991778

  • Royal Hallamshire Hospital, Sheffield, United Kingdom

    Contact: Study coordinator (Dr Chris McDermott, Doctor of medicine) · +44 114 226 1049
צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)